SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT


                       PURSUANT TO SECTION 13 OR 15(D) OF
                     THE SECURITIES AND EXCHANGE ACT OF 1934

                        Date of Report: October 4, 1999

                        (Date of earliest event reported)


                                  OXiGENE, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                   000-21990                  13-3679168
- ----------------------------      ----------------        ----------------------
(State or other jurisdiction      (Commission File            (IRS Employer
     of incorporation)                 Number)            Identification Number)

One Copley Place, Suite 602, Boston, Massachusetts               02116
- --------------------------------------------------              ----------
(Address of principal executive offices)                        (Zip Code)

Registrant's telephone number, including area code:  (617) 536-9500



Item 5.  Other Materially Important Events

     On October 4, 1999, the Registrant issued a press release,  a copy of which
is attached  hereto as Exhibit  99.1,  announcing  interim  results of a Phase I
clinical trial for its Combretastatin A4 Prodrug.

     Certain  statements  made in this press release that may relate to clinical
trial outcomes,  therapeutic applications and outcomes,  governmental approvals,
potential market size and  commercialization  are  forward-looking  and are made
pursuant to the safe harbor  provisions of the Securities  Litigation Reform Act
of 1995.  Such  statements  involve  risks  and  uncertainties  that may  differ
materially from those set forth in these statements.  As described  elsewhere in
the Registrant's  filings with the Securities and Exchange  Commission,  Phase I
clinical  trials  represent the first use of a drug in humans and include only a
small number of patients for the purpose of determining the  preliminary  safety
profile of a drug. The results of early stage clinical  testing of drugs are not
necessarily predictive of results that will be obtained from subsequent testing,
and the FDA may require  modification,  suspension or  termination of subsequent
clinical  trials.  There can be no assurance  that future  clinical  trials will
demonstrate the safety and efficacy of a drug or the ability to obtain necessary
regulatory  approvals of such drugs.  In addition,  the  economic,  competitive,
governmental,  technological  and other factors  identified in the  Registrant's
filings with the  Securities  and Exchange  Commission  could affect the results
reflected in such forward-looking statements.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits

         (c)  Exhibits.

              99.1  Press release of the Registrant, dated October 4, 1999.



     Pursuant to the  requirements  of the  Securities  Exchange Act of 1934, as
amended,  the  registrant has duly caused this report to be signed on its behalf
by the undersigned herewith duly authorized.

Date:  October 5, 1999                      OXiGENE, INC.
                                            (Registrant)


                                            By:  /s/ Bo Haglund
                                                 -------------------------------
                                                 Bo Haglund
                                                 Chief Financial Officer



                                  EXHIBIT INDEX


Exhibit

99.1  Press release of the Registrant, dated October 4, 1999.